A single peripheral nerve block (PNB) injection that provides targeted pain relief for more than three days while keeping more of the therapy where it’s needed, minimizing systemic drug exposure, and reducing reliance on opioids.
Localized formulation
Forms a localized reservoir that remains at the injection site.
Controlled release
Gradually releases therapeutic agent over multiple days.
Targeted therapeutic exposure
Maximizes local efficacy while minimizing systemic exposure.
where it matters most.
Precision therapeutic drug delivery
Advancing INSB200™ toward IND submission in Q3 2026 and initiation of a Phase 1/2 clinical trial in Q4 2026, with post-surgical pain management serving as the lead clinical validation of InSitu’s broader localized delivery platform.
CURRENT FOCUS
Peripheral nerve block (PNB) delivered once.
Single Injection
Provides targeted pain relief for greater than three days and up to five days.
Sustained relief
Minimized exposure
Keeps more of the therapy where it’s needed, minimizing systemic drug exposure.
Opioid-sparing
Designed to reduce reliance on opioids and their side effects.
Four reasons InSitu is positioned for a near-term value inflection
1. Large, underserved market
A significant unmet need remains for longer-duration, non-opioid management of post-operative pain.
2. Near-term clinical catalysts
IND submission planned for Q3 2026, with initiation of the Phase 1/2 clinical trial targeted for Q4 2026.
Development strategy designed to leverage the established safety profile of the active agent while demonstrating the advantages of InSitu’s proprietary platform.
3. Defined regulatory 505(b)(2) strategy
INSB200™ is the lead clinical application of InSitu’s site-specific delivery platform, with potential to support future localized therapeutic programs.
4. Platform-validated upside
LEAD CLINICAL PROGRAM
INSB200™
A new approach to sustained PNB
A sustained-release local anesthetic for Peripheral Nerve Blocks
INSB200™ is designed to improve post-operative pain management through controlled, localized delivery of ropivacaine.
Designed for peripheral nerve block administration
Targeting more than three days and up to five days of localized analgesia
Built on controlled localized release of ropivacaine
Advancing toward Phase 1/2 clinical evaluation
Designed to reduce reliance on opioids after surgery
Area | INSB200 (InSitu Biologics) | STANDARD LOCAL ANESTHETIC NERVE BLOCK (Plain) | STANDARD LOCAL ANESTHETIC NERVE BLOCK (Plain)-1 |
|---|---|---|---|
Drug | Ropivacaine in proprietary sustained-release platform | Ropivacaine | Bupivacaine |
Typical duration of pain relief | Targeting more than 3 days up to 5 days | 8-18 hours | 12-24 hours |
How it works | Controlled local release from a sustained-release peripheral nerve block formulation | Immediate release | Immediate release |
Delivery approach | Single peripheral nerve block administration | Single standard nerve block | Single standard nerve block |
Injection site | Peripheral nerve block (PNB) | Peripheral nerve block (PNB) | Peripheral nerve block (PNB) |
Motor function profile | Expected motor block resolution (12-18 hours) and analgesia extends up to 5 days | Motor and analgesic effects typically resolve within hours | Motor and analgesic effects typically resolve within hours |
Cardiotoxicity (systemic exposure) | Designed for localized release to achieve lowest systemic exposure (Cmax), lowest toxicity | Higher peak systemic exposure; higher toxicity | Highest peak systemic exposure; highest toxicity |
Dose / exposure considerations | Designed to maintain safe and effective dose for pain management for more than 3 days and up to 5 days | Immediate local release within 18 hours | Immediate local release within 24 hours |
Platform technology | Yes | No | No |
Potential beyond pain | Yes - platform for multiple therapeutic applications | No | No |
*Comparative information based on publicly available labeling and published literature.
Why INSB200™ Is Different
Comparison of Local Anesthetic Approaches
INSB200™ is designed to extend analgesia through a sustained-release peripheral nerve block formulation, rather than relying on broad tissue infiltration or systemic pain control.
2026
2034+
$89B+
$45B+
$17.5B+
Broad Pain Management & Extended-Release Therapeutics
$133B+
Post-operative Pain Management & Regional Anesthesia
$65B+
$9.6B+
Peripheral Nerve Blocks
Long-acting Injectables
$17.5B+
$65B+
Today
Future
$133B+
GROWTH STRATEGY
TODAY
INSB200™
Peripheral Nerve Block
NEXT
Additional orthopedic procedures
PLATFORM EXPANSION
-
Regional anesthesia
-
Extended-release therapeutics
-
Broader pain management applications
MARKET OPPORTUNITY
A persistent, non-opioid gap in post-surgical pain management
INSB200™ is designed to extend analgesia through a sustained-release peripheral nerve block formulation, rather than relying on broad tissue infiltration or systemic pain control.
Millions of surgical procedures create significant post-operative pain burden and demand for effective recovery protocols.
Providers continue seeking non-opioid options that can reduce opioid reliance without compromising pain control.
Standard local anesthetics often wear off in hours, while meaningful post-surgical pain frequently persists for days.
Sources: (Company estimates and market research) 1. Persistence Market Research. Postoperative Pain Management Market. June 2026. $45.3B in 2026; $67.6B in 2033. 2. DataM Intelligence. Postoperative Pain Management Market. June 10, 2026. $41.2B in 2024; $65.4B in 2033. 3. Cognitive Market Research. Pain Management Therapeutics Market. June 30, 2026. $89.3B in 2026; $132.7B in 2033. 4. Future Market Insights. U.S. Joint Pain Injections Market. June 15, 2026. $2.5B in 2025; $4.8B in 2032.
HIGH-PAIN PROCEDURES
OPIOID-SPARING PRESSURE
DURATION MISMATCH
NEAR-TERM CLINICAL MILESTONES
A clear path from IND submission to clinical value creation
Q3 2026
IND Submission and Expected Clearance
Submission of the IND application and expected clearance in advance of INSB200™ clinical trial.
First patient enrolled in the Phase 1/2 clinical study evaluating dosing, safety, and preliminary efficacy in bunionectomy patients.
Q4 2026
Phase 1/2 Clinical Trial Initiation
2027
Clinical Execution
Advancement of the Phase 1/2 program in bunionectomy patients and generation of key clinical data.
Late 2027 / Early 2028
Value Inflection Point
Anticipated Phase 1/2 data readout expected to drive value inflection and inform Phase 3 development and strategic opportunities.
Beyond
Clinical Data & Strategy
Phase 3 clinical trial, commercial development, and preparation of NDA.
Targeting more than 3 and up to 5 days of localized analgesia following bunionectomy surgery.
BUNIONECTOMY STUDY
NEAR-TERM CLINICAL MILESTONES
Backed By Trusted Strategic Partners
InSitu collaborates with leading organizations across research, development, manufacturing, and advisory to accelerate INSB200™ and our platform toward clinical and commercial success.
Our contract development and manufacturing partner supporting formulation development and GMP production scalability.
August Bio
CDMO Partner
PRC Clinical
Clinical Trials
PRC Clinical provides personalized CRO services and advanced technologies to streamline clinical trials.
Baker Tilly Virchow Krause, LLP
Audit & Tax Partner
Providing audit, assurance, and tax services to support financial integrity, compliance, and growth.
Our corporate legal partner providing strategic guidance across corporate, transactional, and regulatory matters.
Faegre Drinker
Corporate Counsel
Carlson Caspers
Intellectual Property
Delivering intellectual property counseling and litigation to safeguard innovation, assets, and growth.
Expert perspectives on the future of sustained-release drug delivery
recognized by leaders in Regional Anesthesia
In post-operative pain management, the clinical need is clear: patients and physicians need longer-lasting, localized pain control options that can reduce reliance on systemic opioids without compromising recovery.
Jacob Hutchins, MD, MHA
Executive Medical Director, M Health Ambulatory Surgery Center; Anesthesiologist, University of Minnesota Medical Center, Fairview
Duration remains one of the major practical limitations of peripheral nerve blocks. A single-administration approach designed to provide sustained local anesthetic release over several days could represent an important advance.
Jeff Gadsden, MD
Chief, Division of Orthopedic, Plastic and Regional Anesthesia; Attending Anesthesiologist, Duke University Medical Center
TEAM, BOARD & ADVISORS
Experienced leadership and clinical credibility
LEADERSHIP TEAM
Experience across drug development, biomaterials, company operations, and clinical-stage execution.
BOARD OF DIRECTORS
Strategic governance and life sciences leadership supporting InSitu’s next stage of growth.
MEDICAL ADVISORY BOARD
Clinicians and translational experts guiding clinical relevance, study design, and development strategy.
